Inhibition of EGFR Signaling Protects from Mucormycosis
Tonya N. Watkins(University of Maryland, Baltimore), Vincent M. Bruno(University of Maryland, Baltimore), Teclegiorgis Gebremariam(University of California, Los Angeles), Ashraf S. Ibrahim(University of California, Los Angeles), Sondus Alkhazraji(The Lundquist Institute), Karen T. Graf(University of Maryland, Baltimore), Abdullah Alqarihi(The Lundquist Institute), Vonetta L. Edwards(University of Maryland, Baltimore), Marc Swidergall(Los Angeles Harbor College), Abrar I. Alsaadi(The Lundquist Institute), Amol C. Shetty(University of Maryland, Baltimore), Scott G. Filler(University of California, Los Angeles)
Cited by 69
Related Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i>
|New England Journal of Medicine|2006|1.5k
Guidelines for Treatment of Candidiasis
|Clinical Infectious Diseases|2004|1.4k
Pathogenesis of Mucormycosis
|Clinical Infectious Diseases|2012|806